Introduction: LANRELO7484 is an ongoing, observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) in South Africa (SA).
Aim(s): The study aims to evaluate patients’ level of satisfaction and symptomatic response with diarrhoea and/or flushing when treated with Lanreotide Autogel over a six-month period. Quality of life (QoL), exposure to treatment and safety of Lanreotide Autogel in patients with GEP-NET treated with Lanreotide Autogel are also being measured.
Materials and methods: This is a national, ongoing, multi-centre, prospective observational cohort study involving 11 oncology sites. The decision on treatment is made in accordance with routine clinical practice at the centre concerned. Patients are followed up for 6 months after commencing treatment with Lanreotide Autogel. The data is collected prospectively at a baseline visit, 3 months (3M) and 6 months (6M). The QoL data reported in this abstract is an interim analysis of the data available on the 7th of August 2017 for 23 patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Monique Nel
, Jacobs C
, Rapoport B
, Fourie S
, Szpak W
, Rodrigues S
, Pirjol A
, Narsai N
, Harris J
, Botha M
, Jonas N
, McMaster A
To read results and conclusion, please login ...
Further abstracts you may be interested in